(GILD) Gilead Sciences - Overview

Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NASDAQ (USA) | Market Cap: 169.226m USD | Total Return: 27.6% in 12m

Stock Antivirals, Oncology, Rare Diseases
Total Rating 65
Safety 86
Buy Signal -0.06
Drug Manufacturers - General +6.3
Biotechnology +1.0
Market Cap: 169,226m
Avg Trading Vol: 822M USD
ATR: 2.46%
Peers RS (IBD): 46.8
Risk 5d forecast
Volatility27.3%
Rel. Tail Risk-5.14%
Reward TTM
Sharpe Ratio0.84
Alpha20.32
Character TTM
Beta0.242
Beta Downside0.690
Drawdowns 3y
Max DD26.59%
CAGR/Max DD0.89
EPS (Earnings per Share) EPS (Earnings per Share) of GILD over the last years for every Quarter: "2021-03": 2.08, "2021-06": 1.87, "2021-09": 2.65, "2021-12": 0.69, "2022-03": 2.12, "2022-06": 1.58, "2022-09": 1.9, "2022-12": 1.67, "2023-03": 1.37, "2023-06": 1.66, "2023-09": 2.29, "2023-12": 1.72, "2024-03": -1.32, "2024-06": 2.01, "2024-09": 2.02, "2024-12": 1.9, "2025-03": 1.81, "2025-06": 2.01, "2025-09": 2.47, "2025-12": 1.86, "2026-03": 0,
EPS CAGR: -17.43%
EPS Trend: -9.4%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of GILD over the last years for every Quarter: 2021-03: 6423, 2021-06: 6217, 2021-09: 7421, 2021-12: 7244, 2022-03: 6590, 2022-06: 6260, 2022-09: 7042, 2022-12: 7389, 2023-03: 6352, 2023-06: 6599, 2023-09: 7050, 2023-12: 7114, 2024-03: 6686, 2024-06: 6953, 2024-09: 7545, 2024-12: 7569, 2025-03: 6667, 2025-06: 7081, 2025-09: 7769, 2025-12: 7925, 2026-03: null,
Rev. CAGR: 5.04%
Rev. Trend: 64.4%
Last SUE: 1.06
Qual. Beats: 2
Description: GILD Gilead Sciences

Gilead Sciences, Inc. (GILD) is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs globally. The biopharmaceutical sector is characterized by lengthy and costly research and development cycles.

Its product portfolio includes treatments for HIV/AIDS (e.g., Biktarvy, Genvoya), COVID-19 (Veklury), and viral hepatitis (e.g., Epclusa, Harvoni). The company also markets oncology drugs (e.g., Yescarta, Trodelvy), and treatments for pulmonary arterial hypertension and fungal infections.

Gilead engages in numerous collaborations, including agreements with Arcus Biosciences, Merck Sharp & Dohme Corp., and Janssen Sciences, reflecting a common business model in biotechnology to share development costs and expand pipelines. These collaborations extend to areas like novel antibody discovery and small molecule therapies.

To gain deeper insights into GILDs market position and financial health, further research on platforms like ValueRay is recommended.

Headlines to Watch Out For
  • HIV product sales drive revenue growth
  • Oncology drug pipeline success impacts future earnings
  • COVID-19 treatment demand fluctuates
  • Regulatory approvals for new therapies boost stock
Piotroski VR‑10 (Strict) 7.0
Net Income: 8.51b TTM > 0 and > 6% of Revenue
FCF/TA: 0.16 > 0.02 and ΔFCF/TA -1.45 > 1.0
NWC/Revenue: 27.42% < 20% (prev 24.93%; Δ 2.49% < -1%)
CFO/TA 0.17 > 3% & CFO 10.02b > Net Income 8.51b
Net Debt (17.03b) to EBITDA (12.89b): 1.32 < 3
Current Ratio: 1.68 > 1.5 & < 3
Outstanding Shares: last quarter (1.25b) vs 12m ago -0.48% < -2%
Gross Margin: 80.80% > 18% (prev 0.78%; Δ 8.00k% > 0.5%)
Asset Turnover: 49.89% > 50% (prev 48.74%; Δ 1.16% > 0%)
Interest Coverage Ratio: 8.28 > 6 (EBITDA TTM 12.89b / Interest Expense TTM 1.02b)
Altman Z'' 3.67
A: 0.14 (Total Current Assets 19.89b - Total Current Liabilities 11.81b) / Total Assets 59.02b
B: 0.23 (Retained Earnings 13.73b / Total Assets 59.02b)
C: 0.14 (EBIT TTM 8.49b / Avg Total Assets 59.01b)
D: 1.00 (Book Value of Equity 36.35b / Total Liabilities 36.41b)
Altman-Z'' Score: 3.67 = AA
Beneish M -3.01
DSRI: 1.09 (Receivables 4.91b/4.42b, Revenue 29.44b/28.75b)
GMI: 0.97 (GM 80.80% / 78.26%)
AQI: 0.97 (AQ_t 0.57 / AQ_t-1 0.58)
SGI: 1.02 (Revenue 29.44b / 28.75b)
TATA: -0.03 (NI 8.51b - CFO 10.02b) / TA 59.02b)
Beneish M-Score: -3.01 (Cap -4..+1) = AA
What is the price of GILD shares? As of April 05, 2026, the stock is trading at USD 139.37 with a total of 7,259,238 shares traded.
Over the past week, the price has changed by +4.07%, over one month by -4.96%, over three months by +18.77% and over the past year by +27.61%.
Is GILD a buy, sell or hold? Gilead Sciences has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy GILD.
  • StrongBuy: 15
  • Buy: 4
  • Hold: 11
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the GILD price?
Wallstreet Target Price 157.4 13%
Analysts Target Price 157.4 13%
GILD Fundamental Data Overview as of 01 April 2026
P/E Trailing = 20.1091
P/E Forward = 15.674
P/S = 5.7476
P/B = 7.5031
P/EG = 0.382
Revenue TTM = 29.44b USD
EBIT TTM = 8.49b USD
EBITDA TTM = 12.89b USD
Long Term Debt = 22.13b USD (from longTermDebt, last quarter)
Short Term Debt = 2.81b USD (from shortLongTermDebt, last quarter)
Debt = 24.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 17.03b USD (from netDebt column, last quarter)
Enterprise Value = 183.21b USD (169.23b + Debt 24.59b - CCE 10.61b)
Interest Coverage Ratio = 8.28 (Ebit TTM 8.49b / Interest Expense TTM 1.02b)
EV/FCF = 19.38x (Enterprise Value 183.21b / FCF TTM 9.46b)
FCF Yield = 5.16% (FCF TTM 9.46b / Enterprise Value 183.21b)
FCF Margin = 32.11% (FCF TTM 9.46b / Revenue TTM 29.44b)
Net Margin = 28.90% (Net Income TTM 8.51b / Revenue TTM 29.44b)
Gross Margin = 80.80% ((Revenue TTM 29.44b - Cost of Revenue TTM 5.65b) / Revenue TTM)
Gross Margin QoQ = 86.84% (prev 79.80%)
Tobins Q-Ratio = 3.10 (Enterprise Value 183.21b / Total Assets 59.02b)
Interest Expense / Debt = 1.04% (Interest Expense 255.0m / Debt 24.59b)
Taxrate = 13.13% (1.29b / 9.80b)
NOPAT = 7.37b (EBIT 8.49b * (1 - 13.13%))
Current Ratio = 1.68 (Total Current Assets 19.89b / Total Current Liabilities 11.81b)
Debt / Equity = 1.09 (Debt 24.59b / totalStockholderEquity, last quarter 22.62b)
Debt / EBITDA = 1.32 (Net Debt 17.03b / EBITDA 12.89b)
Debt / FCF = 1.80 (Net Debt 17.03b / FCF TTM 9.46b)
Total Stockholder Equity = 20.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.42% (Net Income 8.51b / Total Assets 59.02b)
RoE = 41.01% (Net Income TTM 8.51b / Total Stockholder Equity 20.75b)
RoCE = 19.80% (EBIT 8.49b / Capital Employed (Equity 20.75b + L.T.Debt 22.13b))
RoIC = 16.13% (NOPAT 7.37b / Invested Capital 45.71b)
WACC = 6.08% (E(169.23b)/V(193.82b) * Re(6.83%) + D(24.59b)/V(193.82b) * Rd(1.04%) * (1-Tc(0.13)))
Discount Rate = 6.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -33.33 | Cagr: -0.12%
[DCF] Terminal Value 85.57% ; FCFF base≈9.79b ; Y1≈9.39b ; Y5≈9.15b
[DCF] Fair Price = 201.0 (EV 266.54b - Net Debt 17.03b = Equity 249.51b / Shares 1.24b; r=6.08% [WACC]; 5y FCF grow -5.51% → 3.0% )
EPS Correlation: -9.40 | EPS CAGR: -17.43% | SUE: -4.0 | # QB: 0
Revenue Correlation: 64.43 | Revenue CAGR: 5.04% | SUE: 1.06 | # QB: 2
EPS next Quarter (2026-06-30): EPS=2.10 | Chg7d=+0.000 | Chg30d=-0.001 | Revisions Net=-3 | Analysts=19
EPS current Year (2026-12-31): EPS=8.67 | Chg7d=-0.012 | Chg30d=-0.015 | Revisions Net=-1 | Growth EPS=+6.4% | Growth Revenue=+2.6%
EPS next Year (2027-12-31): EPS=9.62 | Chg7d=+0.007 | Chg30d=-0.023 | Revisions Net=-1 | Growth EPS=+11.0% | Growth Revenue=+6.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.0% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = +1.6% (Analyst 4.6% - Implied 3.0%)
External Resources
Dataroma Stockcircle